Importantly, osimertinib combined with sapanisertib (mTOR inhibitor) is being investigated in a phase II study (NCT02503722) for EGFR-mutated NSCLC patients who are resistant to previous first-line osimertinib treatment. Here, EGFR is linked to non-small cell lung carcinoma.